Onco Actu du 11 octobre 2017

	1. Biologie
Study uncovers mutation that supercharges tumor-suppressor [Stanford Medicine] The team’s research also revealed something unexpected: A particular mutation in the p53 gene amplified the protein’s tumor-fighting capabilities, creating a “super tumor suppressor.”
Study Raises Questions About Patient-Derived Xenografts [The Scientist] The study finds that when transplanted into mice, the cancers undergo different genomic changes than they do in human hosts.
	3.3 Prévention - Vaccins
Merck's Gardasil 9 offers at least 6 years of cancer protection, data show [FiercePharma] The study enrolled 14,215 girls and women 16 to 26 years of age. At six years after the first dose, Gardasil 9's efficacy against cervical, vulvar and vaginal cancers related to HPV 31, 33, 45, 52, 58—five additional HPV types above the four covered in the original Gardasil vaccine—ranged from 90% to 98%.
	5. Traitements
Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer [NCI] The trial showed that women with early-stage breast cancer who have cancer cells in one or two sentinel lymph nodes can skip axillary lymph node dissection (ALND) after breast-conserving surgery without affecting their long-term survival.
	5.12.7 Immunothérapies - vaccins
AbbVie bags option on Turnstone oncolytic virus candidates [FierceBiotech] The oncolytic virus field has seen fewer big-ticket deals than other corners of the cancer space, but it is clear the agreement is financially meaningful for Turnstone.
AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology [AbbVie] Taking an innovative approach, Turnstone Biologics engineered its Maraba oncolytic viral immunotherapy to function as both a selective tumor-destroying oncolytic virus and an immune-stimulating T cell vaccine.
	5.2 Pharma
Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy [Xconomy] Besides non-small cell lung cancer, Lilly said during its second quarter earnings conference call that it plans to test the drug in colorectal cancer, pancreas cancer, and advanced lung cancer.
Lilly's breast cancer drug fails to help lung patients [Reuters] The drug, whose chemical name is abemaciclib, was being compared with Roche’s erlotinib, sold under the brand name Tarceva. Verzenio belongs to a newer class of oral medicines called CDK 4/6 inhibitors that block cancer cells’ ability to divide and proliferate.
	5.2.1 Pharma - Partenariats
Broad Institute and Deerfield Management launch innovative partnership to tackle serious unmet medical needs [Broad Institute] New collaboration aims to advance therapeutics by rapidly funding promising, early-stage research.
Deerfield commits $50M-plus to translational drug R&D at the Broad [EndPoints] In the deal announced this morning, Deerfield will invest more than $50 million into projects at the Broad over the next five years. And the biotech investor plans to follow up with support to create new biotechs out of the research, with “significant additional resources” available for development work.
MedImmune and GamaMabs enter licensing agreement to develop antibody drug conjugate targeting cancer [MedImmune] Similar to a navigation system that takes a molecule to a specific address in the body, GamaMabs’ innovative antibodies, in combination with MedImmune’s unique PBD technology, are expected to show a promising capacity to deliver the potent PBD payload to cancer cells expressing a selected target.
	5.4 Traitements - Economie
Cancer-Drug Prices Are at a Tipping Point [Bloomberg] These medicines cost more than $150,000 a year and are set to become available to ever-broader groups of patients. Price competition is only a matter of time.
	6. Lutte contre les cancers
OHSU lures prominent cancer scientist from MD Anderson Cancer Center in Houston [OregonLive] It's taken OHSU five years to lure Mills from the Houston-based MD Anderson Cancer Center, one of the country's biggest cancer centers. "We're really pleased about this one," said Dr. Brian Druker, who leads the Knight Cancer Institute.
Pharma's Puerto Rico problems could mean drug shortages: FDA chief [Reuters] The FDA has warned of 40 drugs made in Puerto Rico that could face shortages, including treatments for cancer, rheumatoid arthritis and HIV, but has not named specific medicines.
	6.6 Publications
Publishers threaten to remove millions of papers from ResearchGate [Nature] Take-down notices “imminent” as lawsuit is filed alleging widespread copyright infringement.
	6.9 Controverses
Is Precision Medicine Possible? [Issues in Science and Technology] Advances in our understanding of the genome suggest that for most public health challenges it may not be.